4//SEC Filing
PORTNOY DAVID 4
Accession 0000950170-25-114029
CIK 0000862692other
Filed
Sep 9, 8:00 PM ET
Accepted
Sep 10, 5:22 PM ET
Size
31.0 KB
Accession
0000950170-25-114029
Insider Transaction Report
Form 4
PORTNOY DAVID
DirectorChairman, Co-CEO10% Owner
Transactions
- Purchase
Common Stock
2025-09-09$4.49/sh+4,815$21,619→ 257,843 total(indirect: By IRA) - Purchase
Common Stock
2025-09-10$4.48/sh+2,087$9,350→ 57,306 total(indirect: By Corporation) - Purchase
Common Stock
2025-09-09$4.49/sh+185$831→ 11,537 total(indirect: As Custodian for son) - Purchase
Common Stock
2025-09-10$4.47/sh+4,817$21,532→ 107,403 total(indirect: By Spouse) - Purchase
Common Stock
2025-09-09$4.49/sh+156$700→ 10,939 total(indirect: As Custodian for son) - Purchase
Common Stock
2025-09-10$4.40/sh+11,035$48,554→ 268,878 total(indirect: By IRA) - Purchase
Common Stock
2025-09-10$4.42/sh+7,178$31,727→ 811,920 total - Purchase
Common Stock
2025-09-08$4.31/sh+5,271$22,718→ 253,028 total(indirect: By IRA) - Purchase
Common Stock
2025-09-09$4.48/sh+156$699→ 11,398 total(indirect: As Custodian for son) - Purchase
Common Stock
2025-09-10$4.48/sh+7,200$32,256→ 160,082 total(indirect: By Corporation)
Holdings
- 50,000
Stock Option
Exercise: $8.08From: 2025-01-21Exp: 2030-01-21→ Common Stock (50,000 underlying) - 164,182(indirect: By 401(k))
Common Stock
- 59,027(indirect: By LLC)
Common Stock
- 26,243
Stock Option
Exercise: $7.53From: 2019-08-30Exp: 2029-08-30→ Common stock (26,243 underlying) - 23,636
Stock Option
Exercise: $7.28From: 2019-12-20Exp: 2029-12-20→ Common Stock (23,636 underlying) - 280,000
Stock Option
Exercise: $12.27From: 2021-12-22Exp: 2028-12-22→ Common Stock (280,000 underlying) - 50,000
Stock Option
Exercise: $4.77From: 2023-01-03Exp: 2028-01-03→ Common Stock (50,000 underlying) - 50,000
Stock Option
Exercise: $4.30From: 2022-12-23Exp: 2027-12-23→ Common Stock (50,000 underlying) - 50,000
Stock Option
Exercise: $6.47From: 2023-12-22Exp: 2028-12-22→ Common Stock (50,000 underlying)
Footnotes (10)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.32, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F10]Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
- [F2]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.49, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F4]Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary.
- [F5]Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary.
- [F6]Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership.
- [F7]Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term.
- [F8]8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026.
- [F9]Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025.
Documents
Issuer
CRYO CELL INTERNATIONAL INC
CIK 0000862692
Entity typeother
Related Parties
1- filerCIK 0001315416
Filing Metadata
- Form type
- 4
- Filed
- Sep 9, 8:00 PM ET
- Accepted
- Sep 10, 5:22 PM ET
- Size
- 31.0 KB